Arcus Biosciences Reports Half‑Year 2026 Financial Results

What Happened
Arcus Biosciences, Inc. (RCUS) filed a Form 8‑K on August 5, 2026 (Item 2.02) to announce its financial results for the six months ended June 30, 2026. The company furnished a press release disclosing those results as Exhibit 99.1 to the 8‑K; the filing was signed by CEO Terry Rosen, Ph.D.

Key Details

• Filing date: August 5, 2026 (Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period disclosed: six months ended June 30, 2026.
• Press release with the financial results is furnished as Exhibit 99.1 and is incorporated by reference.
• Filing signed by Terry Rosen, Ph.D., Chief Executive Officer; filing includes embedded Inline XBRL cover page (Exhibit 104).

Why It Matters
This 8‑K notifies investors that Arcus has publicly released its mid‑year financial results; the press release (Exhibit 99.1) will contain the specific revenue, earnings, cash position and other performance metrics that matter for valuation and near‑term outlook. Retail investors should review the Exhibit 99.1 press release and the company’s quarterly filings for the detailed numbers and any management commentary on results or guidance.